A Quick Look at Today's Ratings for Exact Sciences(EXAS.US), With a Forecast Between $54 to $90
Barclays Maintains Overweight on Exact Sciences, Raises Price Target to $75
Exact Sciences Is Maintained at Sector Perform by RBC Capital
Exact Sciences Is Maintained at Outperform by Evercore ISI Group
Evercore ISI Group Maintains Outperform on Exact Sciences, Raises Price Target to $66
Exact Sciences: Strong Q1 Performance and Promising Outlook Justify Buy Rating
RBC Raises Price Target on Exact Sciences to $54 From $52, Keeps Sector Perform Rating
Exact Sciences Analyst Ratings
Piper Sandler Reaffirms Their Buy Rating on Exact Sciences (EXAS)
Analysts Have Conflicting Sentiments on These Healthcare Companies: Exact Sciences (EXAS), 89bio (ETNB) and Stryker (SYK)
Barclays Maintains Exact Sciences(EXAS.US) With Buy Rating, Raises Target Price to $75
Analysts Offer Insights on Healthcare Companies: CVS Health (CVS), Exact Sciences (EXAS) and Arvinas Holding Company (ARVN)
Research Alert: Despite Mixed Q1 Results, The Raised 2025 Outlook Is Encouraging
Craig-Hallum Maintains Exact Sciences(EXAS.US) With Buy Rating
Analysts Offer Insights on Healthcare Companies: Pfizer (PFE), Phathom Pharmaceuticals (PHAT) and Exact Sciences (EXAS)
Exact Sciences' Stock Resilience and Legal Outlook Drive Buy Rating
TD Cowen Maintains Exact Sciences(EXAS.US) With Buy Rating, Cuts Target Price to $75
Bernstein Reaffirms Their Buy Rating on Exact Sciences (EXAS)
Exact Sciences Is Maintained at Overweight by Barclays
Mizuho Initiates Exact Sciences at Outperform With $60 Price Target